Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals has reported Total Non-Current Liabilities for 10 years, with the latest figure at $2.8 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 17.52% year-over-year to $2.8 billion in Q2 2026; TTM through Jun 2026 was $2.8 billion, a 17.52% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 15.5% from the prior year.
• Total Non-Current Liabilities was $2.8 billion for Q2 2026 at Amneal Pharmaceuticals, roughly flat from $2.8 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $2.9 billion in Q1 2022, with the low at $2.3 billion in Q1 2025.
• Average Total Non-Current Liabilities over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities dropped 12.44% in 2024, then climbed 18.03% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $2.8 billion in 2022, then decreased by 9.62% to $2.6 billion in 2023, then fell by 5.79% to $2.4 billion in 2024, then climbed by 15.5% to $2.8 billion in 2025, then slipped by 0.52% to $2.8 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $2.8 billion (Q2 2026), $2.8 billion (Q1 2026), and $2.8 billion (Q4 2025), per Business Quant data.